FDA Accepts NDA for Takeda’s Maribavir

Takeda is one step closer to winning approval for its post-transplant cytomegalovirus (CMV) infection treatment, Maribavir. This morning, the company announced the U.S. Food and Drug Administration accepted its New Drug Application following positive Phase III data.